RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Matched conditions: RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Combination therapy shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation therapy could help patients whose non-Hodgkin lymphoma had returned or stopped responding to treatment. Seventeen adults with aggressive lymphoma types received bo…
Matched conditions: RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug combo shows promise for Tough-to-Treat lymphomas
Disease control CompletedThis phase 1 trial tested the safety and best dose of olaparib when added to high-dose chemotherapy for 50 patients with lymphomas that returned or didn't respond to treatment. All patients were scheduled for a stem cell transplant. The goal was to see if the combination could wo…
Matched conditions: RECURRENT T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC